World Health Organization Approves Clinical Trials for Two New Ebola Vaccines

Health17 sourcesNov 4, 2026

Leans rightFactual rigor 51/100

The Story

The World Health Organization has approved clinical trials for two new Ebola vaccine candidates, specifically ChAdOx1 BDBV developed by the University of Oxford with the Serum Institute of India, and Moderna's mRNA-1469.

World Health Organization chief Tedros Adhanom Ghebreyesus announced the recommendation from expert groups during a press briefing. The Democratic Republic of the Congo's National Institute for Biomedical Research is leading the trial with backing from the World Health Organization and other partners. The outbreak is driven by the rare Bundibugyo strain, for which no approved vaccine or specific treatment previously existed.

What they agree on

All sources report that the World Health Organization approved clinical trials for two new Ebola vaccines, ChAdOx1 BDBV and Moderna's mRNA-1469.
Official reports state that a British healthcare worker in the Democratic Republic of the Congo tested positive for Ebola and is scheduled for medical evacuation to the United Kingdom.
Health authorities in Israel confirm that two individuals tested negative for Ebola after returning from the Democratic Republic of the Congo.

Where they split

The Guardian and Reuters place primary emphasis on the medical evacuation of the British healthcare worker, while other outlets lead with the World Health Organization vaccine trial approvals.
The Associated Press and Agence France-Presse devote specific coverage to international travel restrictions and the United States attestation requirement, which other outlets omit.
Nature News and independent scientific sources provide additional coverage regarding a concurrent anthrax outbreak affecting hippopotamuses in Virunga National Park, while mainstream news services focus exclusively on the human Ebola epidemic.